General Information
Drug ID
DR01163
Drug Name
Octreotide
Synonyms
Octreotide; Octreotide acetate; Octreotidum; Octreotida; 79517-01-4; Sandostatin; UNII-RWM8CCW8GP; SMS 201-995; Longastatin; RWM8CCW8GP; SMS-201-995; CHEMBL1680; Octreotidum [Latin]; MFCD00871400; Octreotida [Spanish]; Octrotide; Octreotide [USAN:INN:BAN]; Octreotide-LAR; AC1L9M4X; Octreotide, >=98% (HPLC); SCHEMBL10044649; DEQANNDTNATYII-OULOTJBUSA-N; HMS2090C09; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
Drug Type
Small molecular drug
Indication Maintenance of normal sinus rhythm [ICD11: BC81.3] Approved [1]
Therapeutic Class
Anabolic Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=448601"></iframe>
3D MOL 2D MOL
Formula
C49H66N10O10S2
Canonical SMILES
CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O
InChI
InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
InChIKey
DEQANNDTNATYII-OULOTJBUSA-N
CAS Number
CAS 83150-76-9
Pharmaceutical Properties Molecular Weight 1019.2 Topological Polar Surface Area 383
Heavy Atom Count 71 Rotatable Bond Count 17
Hydrogen Bond Donor Count 13 Hydrogen Bond Acceptor Count 14
XLogP
1
PubChem CID
448601
PubChem SID
104061285 , 104591919 , 11430106 , 125434068 , 126670761 , 127723791 , 134337693 , 135652471 , 137240521 , 139157534 , 179293772 , 184545267 , 223682643 , 226973283 , 242084564 , 252218803 , 50065276 , 50992191 , 53788390 , 5480746 , 56200952 , 57402265 , 7847508 , 85209213 , 9514
TTD Drug ID
D02XIY
DT(s) Transporting This Drug MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
References
1 Octreotide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.